Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-19

Not sitting back either !! In Vinnie we trust...

The success of the BTX 1702 study significantly adds to the Botanix pipeline of dermatology products
and with the recent submission of Sofpironium Bromide for FDA approval, helping to accelerate
Botanix’s transition to a revenue generating dermatology company.

Botanix has begun building its commercial capability and is preparing for the important mid-cycle
review with FDA for Sofpironium Bromide which occurs 6 months after filing of the NDA.

The Company continues to review other opportunities to further bolster its pipeline with additional late stage or
revenue producing dermatology products, that can be acquired for modest cost and which contribute
to profitability and value.